This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
1P-ETH-LAD: Difference between revisions
>LockPicker m removed duplicates |
>LockPicker m fixed cs1 error |
||
| Line 20: | Line 20: | ||
This compound likely acts as a [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] [[Agonist#Agonists|partial agonist]]. The [[psychedelic]] effects are believed to come from 1P-ETH-LAD's efficacy at the 5-HT<sub>2A</sub> receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. | This compound likely acts as a [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] [[Agonist#Agonists|partial agonist]]. The [[psychedelic]] effects are believed to come from 1P-ETH-LAD's efficacy at the 5-HT<sub>2A</sub> receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. | ||
1P-ETH-LAD shares many common traits with its parent compound [[LSD]]; it appears to be roughly equal in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable) due to suspected differences in how it is metabolized. Research has shown formation of [[ETH-LAD]] from 1P-ETH-LAD incubated in human serum, suggesting that it functions as a pro-drug.<ref>{{cite | 1P-ETH-LAD shares many common traits with its parent compound [[LSD]]; it appears to be roughly equal in potency as well as similar in mechanism although the progression and duration of effects are compressed (while remaining qualitatively less intense and more manageable) due to suspected differences in how it is metabolized. Research has shown formation of [[ETH-LAD]] from 1P-ETH-LAD incubated in human serum, suggesting that it functions as a pro-drug.<ref>{{cite journal|last1=Brandt|first1=S. D.|last2=Kavanagh|first2=P. V.|last3=Westphal|first3=F.|last4=Elliott|first4=S. P.|last5=Wallach|first5=J.|last6=Stratford|first6=A.|last7=Nichols|first7=D. E.|author7-link=David E. Nichols|last8=Halberstadt|first8=A. L.|year=2017|title=Return of the lysergamides. Part III: Analytical characterization of N<sup>6</sup>‐ethyl‐6‐norlysergic acid diethylamide (ETH‐LAD) and 1‐propionyl ETH‐LAD (1P–ETH‐LAD)|journal=Drug Testing and Analysis|volume=9|issue=10|pages=1641-1649|doi=10.1002/dta.2196|issn=1942-7611}}</ref> | ||
==Subjective effects== | ==Subjective effects== | ||